PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18372278-11	2008	Enalapril and the combination of enalapril plus spironolactone efficiently reduce PAI-1 levels, but the reductions are more pronounced with the combined regimen.	Enalapril	0-9	serpin family E member 1	Homo sapiens	82-87	
19707983-6	2009	RESULTS: In the enalapril group PAI-1 levels were significantly reduced after treatment (11.9 +/- 2.3 U/ml vs. 17.1 +/- 3.0 U/l; P < 0.05).	Enalapril	16-25	serpin family E member 1	Homo sapiens	32-37	
18372278-11	2008	Enalapril and the combination of enalapril plus spironolactone efficiently reduce PAI-1 levels, but the reductions are more pronounced with the combined regimen.	Enalapril	33-42	serpin family E member 1	Homo sapiens	82-87	
11859853-4	2002	PAI-1 decreased significantly in both genders in the enalapril-treated group after two weeks, with a maximum decrease at six months (mean reduction: 31% equal to 9.8 microg x L(-1), CI: 5.2 to 14.5 microg x L(-1), p = 0.0001) and remained significantly lower at 12 months.	Enalapril	53-62	serpin family E member 1	Homo sapiens	0-5	
14747423-7	2004	PAI-1 antigen trended toward being lower with quinapril versus enalapril on day 1 (24.44 +/- 14.96 vs. 36.94 +/- 19.49, respectively, p = 0.059) and was significantly lower on day 3 (17.32 +/- 9.57 vs. 27.49 +/- 9.61, respectively, p = 0.009).	Enalapril	63-72	serpin family E member 1	Homo sapiens	0-5	
11859853-6	2002	The tPA/PAI-1-complex decreased and was significantly lower (mean reduction 0.96 microg x L(-1), CI: 0.36 to 1.56 microg x L(-1), p = 0.003) in the enalapril group after two weeks and six months (p = 0.037).	Enalapril	148-157	serpin family E member 1	Homo sapiens	8-13	
11859853-8	2002	CONCLUSIONS: Enalapril treatment up to one year depressed mass concentrations of PAI-1 and transiently tPA and tPA/PAI-1 complex indicating an improvement of the fibrinolytic balance in both genders with uncomplicated myocardial infarction.	Enalapril	13-22	serpin family E member 1	Homo sapiens	81-86	
11859853-8	2002	CONCLUSIONS: Enalapril treatment up to one year depressed mass concentrations of PAI-1 and transiently tPA and tPA/PAI-1 complex indicating an improvement of the fibrinolytic balance in both genders with uncomplicated myocardial infarction.	Enalapril	13-22	serpin family E member 1	Homo sapiens	115-120	
1873917-4	1991	After captopril (acute) and enalapril (chronic), PAI and PRA increased, PAII decreased, but neither UV-AI nor UV-AII changed.	Enalapril	28-37	serpin family E member 1	Homo sapiens	49-52	
10347337-10	1999	In the enalapril group, there was no significant change in tPA although PAI-1 activity significantly decreased after drug treatment.	Enalapril	7-16	serpin family E member 1	Homo sapiens	72-77	
7661384-3	1995	In the current study the authors have investigated the effect of two ACE inhibitors, captopril and enalapril, on tissue plasminogen activator (tPA) and PAI in 33 congestive heart failure (CHF) patients.	Enalapril	99-108	serpin family E member 1	Homo sapiens	152-155	
32125188-3	2020	In this study, we hypothesized that the beneficial effect of the angiotensin-converting enzyme inhibitor (ACEi) enalapril on PAI-1 levels is mediated by effects on leptin levels.	Enalapril	112-121	serpin family E member 1	Homo sapiens	125-130